<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02293837</url>
  </required_header>
  <id_info>
    <org_study_id>DAIT ITN058AI</org_study_id>
    <nct_id>NCT02293837</nct_id>
  </id_info>
  <brief_title>Tocilizumab (TCZ) in New-onset Type 1 Diabetes</brief_title>
  <acronym>EXTEND</acronym>
  <official_title>Preserving Beta-Cell Function With Tocilizumab in New-onset Type 1 Diabetes (ITN058AI)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Immune Tolerance Network (ITN)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Type 1 diabetes mellitus (T1DM) is an autoimmune disease. Based on previous research, study
      doctors think that giving medicines to affect the immune system soon after diabetes is
      diagnosed may stop, delay or decrease the destruction of beta cells, resulting in better
      glucose control.

      Researchers believe that tocilizumab could have some effect on the cells in the immune system
      that are thought to be involved in the development of type 1 diabetes. This study will test
      whether tocilizumab can help preserve or delay destruction of remaining beta cells in people
      recently diagnosed type 1 diabetes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Staggered enrollment is planned for this trial.

      Prior to initiating the study in the pediatric age group (6-17 years old), 30-99 eligible
      adults (ages 18-45 years) will be randomized 2:1 to tocilizumab or placebo, respectively.
      Once the first thirty adult participants have completed 12 weeks of treatment, the FDA and
      Data and Safety Monitoring Board (DSMB) will review available data (e.g., interim analysis)
      to weigh potential risks and benefits before opening the trial to pediatric participants.

      As of ≥ May 15, 2017: Study enrollment is limited to participants ages 6 to 17 years
      inclusive.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2015</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>2-Hour C-peptide Area Under the Curve (AUC) Result in Response to Standardized Mixed Meal Tolerance Test (MMTT)</measure>
    <time_frame>Week 52</time_frame>
    <description>The mean 2-hour C-peptide AUC, measured in pmol/mL, computed by dividing the total AUC by 120 minutes</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>MMTT-stimulated mean 2-hour C-peptide AUC</measure>
    <time_frame>At weeks 12, 24, and 104</time_frame>
    <description>Mixed-meal tolerance test (MMTT) area under the curve (AUC) computation per protocol.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MMTT-stimulated mean 2-hour C-peptide AUC assessed longitudinally</measure>
    <time_frame>At weeks 12, 24, 39, 52, 78, and 104</time_frame>
    <description>Mixed-meal tolerance test (MMTT) area under the curve (AUC) computation per protocol.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MMTT-stimulated peak and 4-hour C-peptide AUC for subjects ≥12 years old</measure>
    <time_frame>At weeks 52 and 104</time_frame>
    <description>Mixed-meal tolerance test (MMTT) area under the curve (AUC) computation per protocol.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin Use in Units Per Kilogram Body Weight Per Day</measure>
    <time_frame>At weeks 12, 24, 39, 52, 78, and 104</time_frame>
    <description>The need to use exogenous insulin is an indication that the body is not producing enough endogenous insulin. Higher amounts of insulin use indicate higher disease activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glycemic Control</measure>
    <time_frame>At weeks 12, 24, 39, 52, 78 and 104</time_frame>
    <description>As determined by blood glucose levels over time.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemoglobin A1c levels</measure>
    <time_frame>At weeks 12, 24, 39, 52, 78 and 104</time_frame>
    <description>Glycosylated hemoglobin (HbA1c) is a measure of the average plasma concentration of blood sugar (glucose) over the previous three months and measures the level of optimal management of underlying disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Adverse Events (AEs) related to infusion reactions and hypersensitivity</measure>
    <time_frame>Baseline [pre-treatment initiation] to 104 Weeks</time_frame>
    <description>As defined per protocol.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of all AEs</measure>
    <time_frame>Baseline [pre-treatment initiation] to 104 weeks</time_frame>
    <description>As defined per protocol.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of all AEs.</measure>
    <time_frame>Baseline [pre-treatment initiation] to 104 weeks</time_frame>
    <description>As defined per protocol.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">133</enrollment>
  <condition>Type 1 Diabetes Mellitus</condition>
  <condition>New-onset Type 1 Diabetes Mellitus</condition>
  <condition>T1DM</condition>
  <condition>T1D</condition>
  <arm_group>
    <arm_group_label>Tocilizumab (TCZ)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive intravenous (IV) infusions of either 8.0 mg/kg (body weight ≥30 kg) or 10.0 mg/kg (body weight &lt;30kg) tocilizumab every 4 weeks for 24 weeks. Participants will also receive standard intensive diabetes management.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tocilizumab Placebo Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will receive IV infusions of either 8.0 mg/kg (body weight ≥ 30kg) or 10.0 mg/kg (body weight &lt;30kg) placebo every 4 weeks for 24 weeks. Participants will also receive standard intensive diabetes management.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tocilizumab (TCZ)</intervention_name>
    <description>Subjects assigned to this group will receive tocilizumab intravenous (IV) infusions of either 8.0 mg/kg (body weight ≥ 30kg) or 10.0 mg/kg (body weight &lt;30kg) every 4 weeks for 24 weeks.</description>
    <arm_group_label>Tocilizumab (TCZ)</arm_group_label>
    <other_name>Actemra®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Subjects assigned to this group will receive placebo intravenous (IV) infusions of either 8.0 mg/kg (body weight ≥ 30kg) or 10.0 mg/kg (body weight &lt;30kg) every 4 weeks for 24 weeks.</description>
    <arm_group_label>Tocilizumab Placebo Group</arm_group_label>
    <other_name>Placebo for Tocilizumab</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female aged 6-45 years*

             -*Current Institutional Review Board (IRB)-approved age eligibility criteria is
             restricted to subjects 6 to 17 years of age at time of study enrollment

          2. Diagnosis of type 1 diabetes mellitus (T1DM), using the American Diabetes Association
             T1DM criteria, within 100 days of study enrollment

          3. Positive for at least one diabetes-related autoantibody, including but not limited to:

               1. Glutamate decarboxylase (GAD-65)

               2. Insulin, if obtained within 10 days of the onset of exogenous insulin therapy

               3. Insulinoma antigen-2 (IA-2)

               4. Zinc transporter-8 (ZnT8)

          4. Peak stimulated C-peptide level ≥ 0.2 pmol/mL following a mixed-meal tolerance test
             (MMTT) conducted at least 21 days from diagnosis and within 37 days of randomization
             (V0)

          5. Signed informed consent (and informed assent of minor, if applicable).

        Exclusion Criteria:

          1. Severe reaction or anaphylaxis to human, humanized or murine monoclonal antibodies

          2. History of malignancy or serious uncontrolled cardiovascular, nervous system,
             pulmonary, renal, or gastrointestinal disease, or significant dyslipidemia

          3. Any history of recent serious bacterial, viral, fungal, or other opportunistic
             infections

          4. Have serologic evidence of current or past HIV (Human immunodeficiency virus),
             Hepatitis B, or Hepatitis C

          5. Positive QuantiFERON Tuberculosis (TB) test, history of TB, or active TB infection

          6. Active infection with Epstein-Barr virus (EBV) as defined by EBV viral load ≥10,000
             copies per mL of whole blood

          7. Active infection with Cytomegalovirus (CMV) as defined by CMV viral load ≥10,000
             copies per mL of whole blood

          8. Diagnosis of liver disease or elevated hepatic enzymes, as defined by Alanine
             aminotransferase (ALT), Aspartate aminotransferase (AST), or both &gt; 1.5 x the upper
             limit of age-determined normal (ULN) or total bilirubin &gt; ULN

          9. Current or prior treatment that is known to cause a significant, ongoing change in the
             course of T1D or immunologic status

         10. Current or prior (within last 30 days) use of drugs other than insulin to treat
             hyperglycemia (e.g. metformin, sulfonylureas, glinides, thiazolidinediones, exenatide,
             liraglutide, Dipeptidyl peptidase-4 Intravenous (DPP-IV) inhibitors, or amylin)

         11. Current use of any medication known to significantly influence glucose tolerance
             (e.g., atypical antipsychotics, diphenylhydantoin, niacin)

         12. Any of the following hematologic abnormalities, confirmed by repeat tests:

               1. White blood count &lt;3,000/microL or &gt;14,000/microL

               2. Lymphocyte count &lt;500/microL

               3. Platelet count &lt;150,000 /microL

               4. Hemoglobin &lt;8.5 g/dL

               5. . Neutrophil count &lt;2,000 cells/microL.

         13. Females who are pregnant, lactating, or planning on pregnancy during the 2- year study
             period

         14. History or diagnoses of other autoimmune diseases with the exception of stable thyroid
             or celiac disease

         15. History of alcohol, drug or chemical abuse within 1 year prior to study eligibility
             screening evaluation

         16. Any medical or psychological condition that in the opinion of the principal
             investigator would interfere with safe completion of the trial

         17. Prior participation in a clinical trial that could increase risks associated with this
             clinical trial

         18. Receipt of live vaccine (e.g. varicella, measles, mumps, rubella, cold-attenuated
             intranasal influenza vaccine, bacillus Calmette-Guérin, and small pox) in the 6 weeks
             before randomization

         19. High lipid levels (fasting Low-density lipoprotein (LDL) cholesterol ≥160 mg/dL)

         20. History of significant allergy (e.g. anaphylaxis) to milk or soy proteins.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carla Greenbaum</last_name>
    <role>Study Chair</role>
    <affiliation>Benaroya Research Institute at Virginia Mason: Diabetes Research Program</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jane Buckner, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Benaroya Research Institute at Virginia Mason: Diabetes Research Program</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Glenna Auerback</last_name>
      <phone>415-502-0857</phone>
      <email>Glenna.Auerback@ucsf.edu</email>
    </contact>
    <investigator>
      <last_name>Stephen Gitelman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Trudy Esrey</last_name>
      <phone>650-498-4450</phone>
      <email>tesrey@stanford.edu</email>
    </contact>
    <investigator>
      <last_name>Darrell Wilson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yale University School of Medicine: Diabetes Endocrinology Research Center</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06519</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Linda Rink</last_name>
      <phone>203-737-4510</phone>
      <email>linda.rink@yale.edu</email>
    </contact>
    <investigator>
      <last_name>Kevan Herold, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Miami: Diabetes Research Institute</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Della Matheson</last_name>
      <phone>305-243-3781</phone>
      <email>dmatheso@med.miami.edu</email>
    </contact>
    <investigator>
      <last_name>David Baidal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of South Florida: Diabetes Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emily Eyth</last_name>
      <phone>813-974-2793</phone>
      <email>emilyeyth@health.usf.edu</email>
    </contact>
    <investigator>
      <last_name>Henry Rodriguez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Indiana University Health - Riley Hospital for Children</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Megan Hildinger</last_name>
      <phone>317-278-7052</phone>
      <email>mhilding@iu.edu</email>
    </contact>
    <contact_backup>
      <last_name>Maria Spall</last_name>
      <email>malnicho@iu.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Linda DiMeglio, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Iowa</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joanne Cabbage</last_name>
      <phone>319-335-7434</phone>
      <email>joanne-cabbage@uiowa.edu</email>
    </contact>
    <investigator>
      <last_name>Eva Tsalikian, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Harvard University, Joslin Diabetes Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>002215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nora Bryant</last_name>
      <phone>671-309-4141</phone>
      <email>Nora.Bryant@joslin.harvard.edu</email>
    </contact>
    <contact_backup>
      <last_name>Brittany Resnick</last_name>
      <email>brittany.resnick@joslin.harvard.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Jason Gaglia, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne Street</last_name>
      <phone>612-625-9709</phone>
      <email>stree065@umn.edu</email>
    </contact>
    <contact_backup>
      <last_name>Janice Leschyshyn</last_name>
      <email>lesch004@umn.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Antoinette Moran, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Mercy Hospital</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marissa Beidelschies</last_name>
      <phone>816-760-5918</phone>
      <email>mkbeidelschies@cmh.edu</email>
    </contact>
    <investigator>
      <last_name>Wayne V. Moore, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University, Naomi Berrie Diabetes Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Pollak</last_name>
      <phone>212-851-5465</phone>
      <email>sjp2174@columbia.edu</email>
    </contact>
    <investigator>
      <last_name>Robin Goland, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olena Kucheruk</last_name>
      <phone>267-426-3909</phone>
      <email>kucheruk@email.chop.edu</email>
    </contact>
    <investigator>
      <last_name>Steven M. Willi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sanford Research</name>
      <address>
        <city>Sioux Falls</city>
        <state>South Dakota</state>
        <zip>57104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Megan Broadbent</last_name>
      <phone>605-328-1359</phone>
      <email>megan.broadbent@sanfordhealth.org</email>
    </contact>
    <contact_backup>
      <last_name>Lynn Bartholow</last_name>
      <email>lynn.bartholow@sanfordhealth.org</email>
    </contact_backup>
    <investigator>
      <last_name>Kurt Griffin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne Brown</last_name>
      <phone>615-969-5816</phone>
      <email>anne.brown@vanderbilt.edu</email>
    </contact>
    <investigator>
      <last_name>William Russell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Benaroya Research Institute</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98101</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marli McCulloch-Olson</last_name>
      <phone>206-342-6943</phone>
      <email>marli@benaroyaresearch.org</email>
    </contact>
    <investigator>
      <last_name>Carla Greenbaum, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Children's Hospital at Westmead: Kids Research Institute</name>
      <address>
        <city>Westmead</city>
        <state>New South Wales</state>
        <zip>Westmead 2145</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nacha Han</last_name>
      <phone>61 2 9845 3907</phone>
      <email>nacha.han@health.nsw.gov.au</email>
    </contact>
    <investigator>
      <last_name>Maria Craig, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lady Cilento Children's Hospital: Department of Endocrinology</name>
      <address>
        <city>South Brisbane</city>
        <state>Queensland</state>
        <zip>4101</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julie Kirby</last_name>
      <phone>617 3069 7513</phone>
      <email>j.kirby@mater.uq.edu.au</email>
    </contact>
    <investigator>
      <last_name>Mark Harris, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Canada</country>
  </removed_countries>
  <link>
    <url>https://www.niaid.nih.gov/</url>
    <description>National Institute of Allergy and Infectious Diseases (NIAID) website</description>
  </link>
  <link>
    <url>https://www.niaid.nih.gov/about/dait</url>
    <description>Division of Allergy, Immunology, and Transplantation (DAIT) website</description>
  </link>
  <link>
    <url>http://www.immunetolerance.org/</url>
    <description>Immune Tolerance Network (ITN) website</description>
  </link>
  <link>
    <url>http://www.extendstudy.org/about-extend</url>
    <description>EXTEND's study-specific ITN website</description>
  </link>
  <link>
    <url>http://www.diabetes.org/diabetes-basics/type-1/?loc=util-header_type1</url>
    <description>American Diabetes Association information on Type 1 Diabetes</description>
  </link>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 13, 2014</study_first_submitted>
  <study_first_submitted_qc>November 17, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 18, 2014</study_first_posted>
  <last_update_submitted>February 16, 2018</last_update_submitted>
  <last_update_submitted_qc>February 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 20, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>interleukin-6 (IL-6) receptor inhibitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The plan is to share data upon completion of the study in: 1.)ImmPort, a long-term archive of clinical and mechanistic data from DAIT-funded grants and contracts; and 2.)TrialShare, a clinical trials research portal developed by the Immune Tolerance Network that makes data from the consortium's clinical trials publicly available.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

